Evidence map›Paper›PMID 29248669›Full record

Trial reportThe Lancet. Haematology2018

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.

Kirsten M Williams, Jennifer Holter-Chakrabarty, Liza Lindenberg, Quyen Duong, Sara K Vesely, Chuong T Nguyen, Joseph P Havlicek, Karen Kurdziel, Juan Gea-Banacloche, Frank I Lin and 9 more

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01338987 (Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01338987 phase2completednot on this map

Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults With Molecular Imaging Evaluation

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2011 to 2020Enrolled76ConditionsMyelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous LeukemiaArmsFirst Allogeneic Bone Marrow Transplant (BMT), Leuprolide, 18F FLT, Cyclophosphamide, Methotrexate
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Radiology. Imaging cancer · 2025
    Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. EJNMMI research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Kirsten M WilliamsChildren's Research Institute, Children's National Health System, Washington, DC, USA. Electronic address: kmwillia@cnmc.org.
Jennifer Holter-ChakrabartyStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Liza LindenbergMolecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
Quyen DuongStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Sara K VeselyStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Chuong T NguyenSchool of Electrical and Computer Engineering, University of Oklahoma, Norman, OK, USA.
Joseph P HavlicekSchool of Electrical and Computer Engineering, University of Oklahoma, Norman, OK, USA.
Karen KurdzielMolecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
Juan Gea-BanaclocheDivision of Infectious Diseases, Mayo Clinic Arizona, AZ, USA.
Frank I LinCancer Imaging Program, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
Daniele N AvilaExperimental Transplantation and Immunology Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
George SelbyStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Christopher G KanakryExperimental Transplantation and Immunology Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
Shibo LiStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Teresa ScordinoStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Stephen AdlerClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, National Cancer Institute Campus at Frederick, Frederick, MD, USA.
Catherine M BollardChildren's Research Institute, Children's National Health System, Washington, DC, USA.
Peter ChoykeMolecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
Ronald E GressExperimental Transplantation and Immunology Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA.
University of Oklahoma Health Sciences Center · USNational Cancer Institute · USNational Institutes of Health · USChildren's National · USUniversity of Oklahoma · USLeidos Biomedical Research Inc. (United States)WinnMed · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michael S. Businelle · 2018 to 2026
$27.1M
Immune ReconstitutionZIABC010525 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GRESS, RONALD · 2009 to 2023
$21.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA225520NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

backgroundHaemopoietic stem-cell transplantation (HSCT) eradicates host haemopoiesis before venous infusion of haemopoietic stem cells (HSCs). The pathway to cellular recovery has been difficult to study in human beings because of risks associated with interventions during aplasia. We investigated whether

methodsEligible patients were aged 18-55 years, had high-risk haematological malignancies. All patients underwent myeloablation followed by HSCT. The imaging primary endpoint was detection of early subclinical engraftment after HSCT with

findingsBetween April 1, 2014, and Dec 31, 2015, 23 patients were enrolled and assessable for toxic effects after completing accrual.

interpretation

fundingNational Institutes of Health, Ben's Run/Ben's Gift, Albert and Elizabeth Tucker Foundation, Mex Frates Leukemia Fund, Jones Family fund, and Oklahoma Center for Adult Stem Cell Research.

Indexed as

Hematopoietic Stem Cell TransplantationPositron-Emission TomographyTomography, X-Ray ComputedAdultDideoxynucleosidesFemaleHematologic NeoplasmsHumansMalePilot ProjectsProspective StudiesTissue DistributionalovudineDideoxynucleosides

Identifiers

PMID29248669
PMCPMC5770195
OpenAlexW2773505062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.